Karus Therapeutics

Karus Therapeutics is a privately-owned biotech company focusing on the development of two potent and selective inhibitors of PI3K and HDAC, with a primary focus on the treatment of inflammatory disease. Karus is also exploring the potential of these PI3K and HDAC inhibitors as new classes of targeted cancer therapies.

The Company is located in Abingdon, Oxfordshire, UK.